MBrace Therapeutics, a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), announced the appointment...
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN),...
Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,...
Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...
Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors announces the appointment of Sean A. MacDonald...
